AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer

Author(s): Samanta Salvi*, Vincenza Conteduca, Cristian Lolli, Sara Testoni, Valentina Casadio, Andrea Zaccheroni, Lorena Rossi, Salvatore Luca Burgio, Cecilia Menna, Giuseppe Schepisi, Ugo De Giorgi

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 9 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Adaptive upregulation of Androgen Receptor (AR) is the most common event involved in the progression from hormone sensitive to Castration-Resistant Prostate Cancer (CRPC). AR signaling remains the main target of new AR signalling-directed therapies such as abiraterone and enzalutamide in CRPC patients.

Objective: In this review, we discuss general mechanisms of resistance to AR-targeted therapies, with a focus on the role of AR Copy Number (CN). We reported methods and clinical applications of AR CN evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker.

Conclusion: Outcomes of CRPC patients are reported to be highly variable as the consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.

Keywords: Androgen receptor, AR copy number, biomarkers, CRPC, prostate cancer, outcome.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 16 October, 2018
Page: [869 - 876]
Pages: 8
DOI: 10.2174/1568009617666171122145852
Price: $65

Article Metrics

PDF: 35